Provider management of menopause after the findings of the Women's Health Initiative

Menopause

Volumn 14, Issue 3, 2007, Pages 441-449

  Rolnick, Sharon J ^a   Jackson, Jody ^a   Kopher, Richard ^b   Defor, Terese A ^a  

^a HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

Attitude of health personnel; Estrogen therapy; Menopause; Physicians' practice patterns

Indexed keywords

ADULT; ARTICLE; CLINICAL PRACTICE; COUNSELING; EPIDEMIOLOGY; FEMALE; GENERAL PRACTICE; GYNECOLOGY; HEALTH EDUCATION; HEALTH PERSONNEL ATTITUDE; HEALTH SERVICE; HUMAN; HUMAN RELATION; MALE; MENOPAUSE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; STATISTICS; UNITED STATES; WOMEN'S HEALTH;

ADULT; ATTITUDE OF HEALTH PERSONNEL; COUNSELING; FAMILY PRACTICE; FEMALE; GYNECOLOGY; HEALTH CARE SURVEYS; HEALTH EDUCATION; HUMANS; MALE; MENOPAUSE; MIDDLE AGED; MIDWESTERN UNITED STATES; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL-PATIENT RELATIONS; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 34447259817     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31802cc7bc     Document Type: Article

References (29)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu Rev Public Health 2005;26:115-140.
3. Hormone therapy for the prevention of chronic conditions in post-menopausal women: recommendations from the US Preventive Services Task Force. Ann Intern Med 2005;142:855-860.
4. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 2003;289:537-538.
5. Jneid H, Thacker HL. Coronary artery disease in women: different, often undertreated. Cleve Clin J Med 2001;68:441-448.
6. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160:3315-3325.
7. Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause 2005;12:399-404.
8. Schonberg MA, Davis RB, Wee CC. After the Women's Health Initiative: decision making and trust of women taking hormone therapy. Womens Health Issues 2005;15:187-195.
9. Wei F, Miglioretti DL, Connelly MT, et al. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr 2005:106-112.
10. Hartsfield CL, Connelly MT, Newton KM, Andrade SE, Wei F, Buist DS. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. J Natl Cancer Inst Monogr 2005:113-115.
11. Wolcott HF. Transforming Qualitative Data: Description, Analysis, and Interpretation. Thousand Oaks, CA: Sage Publications, 1994.
12. Roumie CL, Grogan EL, Falbe W, et al. A three-part intervention to change the use of hormone replacement therapy in response to new evidence. Ann Intern Med 2004;141:118-125.
13. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983-1988.
14. Rolnick SJ, O'Connor PJ, Jackson JM, Boyle RG, Pronk NP, Loes LM. Early- and late-stage breast cancer in a managed care setting in relation to mammography screening. Cancer Detect Prev 1998;22:495-498.
15. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650.
16. Crandall C. Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. J Womens Health (Larchmt) 2003;12:723-747.
17. Blumel JE, Castelo-Branco C, Chedraui PA, et al. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause 2004;11:57-61.
18. Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med 2003;348:579-580.
19. HRT: what are women (and their doctors) to do? Lancet 2004;364:2069-2070.
20. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115.
21. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86, 123-133.
22. Peterson HB, Thacker SB, Corso PS, Marchbanks PA, Koplan JP. Hormone therapy: making decisions in the face of uncertainty. Arch Intern Med 2004;164:2308-2312.
23. Kim C, Kwok YS. Decision analysis of hormone replacement therapy after the Women's Health Initiative. Am J Obstet Gynecol 2003;189:1228-1233.
24. Speroff L. The impact of the Women's Health Initiative on clinical practice. J Soc Gynecol Investig 2002;9:251-253.
25. Notelovitz M. Clinical opinion: the biologic and pharmacologic principles for age-adjusted long-term estrogen therapy. MedGenMed 2006;8:84.
26. Leong SL, Erickson DR, Pees RC. Hormone replacement therapy: the right choice for your patient? J Fam Pract 2005;54:428-436.
27. Hess R, Chang CC, Conigliaro J, McNeil M. Understanding physicians' attitudes towards hormone therapy. Womens Health Issues 2005;15:31-38.
28. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-366.
29. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44.